Pfizer (PFE) stock prices updated...
 

Pfizer stock price

Pfizer latest news:


  • 08/17/2017 14:22:05

    BRIEF-Pfizer receives FDA approval for BESPONSA (inotuzumab ozogamicin)

    * Pfizer receives U.S. FDA approval for BESPONSA (inotuzumab ozogamicin) Source text for Eikon: Further company coverage:

  • 08/17/2017 11:40:31

    BRIEF-U.S. FDA approves Pfizer's leukemia drug Besponsa ‍​

    U.S. Food and Drug Administration: * U.S. FDA approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ‍​. * FDA granted the approval of Besponsa to Pfizer Inc.‍​. * Prescribing information for Besponsa includes a boxed warning that severe liver damage occurred in some patients who took Besponsa‍​. * Boxed warning also i...

  • 08/14/2017 16:16:16

    BRIEF-Soros Fund Management dissolves share stake in Tesla, Pfizer, ConocoPhillips

    Soros Fund Management: * Soros Fund Management dissolves share stake in Tesla Inc (TSLA) - SEC filing. * Soros Fund Management dissolves share stake in Pfizer Inc (PFE). * Soros Fund Management dissolves share stake in ConocoPhillips.

  • 08/14/2017 15:26:44

    Tepper's Appaloosa dumps Snap Inc., stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others. Related: Active-managers have a new favorite toolMarket Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:14:19

    Tepper's Appaloosa dumps Snap Inc. stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 14:41:40

    BRIEF-Appaloosa dissolves share stake in Snap Inc, Pfizer Inc

    Appaloosa Lp: * Appaloosa Lp dissolves class a share stake in Snap Inc (SNAP) - SEC Filing. * Appaloosa Lp ups share stake in Apple Inc (AAPL) to 625,000 from 300,000.

  • 08/09/2017 09:47:54

    Mexico watchdog finds big pharma faces no competition on some drugs

    Pharmaceutical companies including GlaxoSmithKline, Pfizer and Sanofi-Aventis face no competition for certain drugs in Mexico from generics that are readily available elsewhere, a senior Mexican anti-trust official said on Wednesday.

  • 08/01/2017 11:36:25

    Key drug sales push Pfizer profit up 50 percent

    Rising sales of several key drugs, lower one-time charges and reduced manufacturing costs helped drugmaker Pfizer raise its profit 50 percent in the second quarter

  • 08/01/2017 11:35:11

    Key drug sales push Pfizer profit up 50 percent

    Pfizer is reporting second-quarter profit of $3.07 billion.

  • 07/25/2017 15:36:13

    Adviser charged with insider trading on Pfizer-King deal pleads guilty

    NEW YORK, July 25 (Reuters) - A Long Island, New York, investment adviser accused of engaging in insider trading after being tipped off about Pfizer Inc's $3.6 billion acquisition of King Pharmaceuticals Inc pleaded guilty on Tuesday, federal prosecutors said.

  • 07/04/2017 11:51:50

    Pfizer receives token payment to exit Brazil venture, sources say

    SAO PAULO (Reuters) - Pfizer Inc has agreed to exit Laboratório Teuto Brasileiro SA for a token amount after failing to find a buyer for the 40 percent stake it held in the Brazilian generic drugmaking joint venture, two people with knowledge of the matter said on Tuesday.

  • 06/20/2017 17:19:51

    Exelixis's Cabometyx Positive for First-Line Kidney Cancer

    Exelixis Inc EXEL announced results from an analysis of the data from the phase II trial CABOSUN The study compared Cabometyx to Pfizer s PFE Sutent in the first line treatment of intermediate or poor risk advanced renal cell carcinoma RCC patients We note that Cabometyx tablets

  • 06/14/2017 11:27:11

    BRIEF-Pfizer to have exclusive rights to distribute, commercialize CRESEMBA in Europe

    * Pfizer receives exclusive commercialization rights in Europe for CRESEMBA, a novel treatment for potentially life-threatening fungal infections among immunocompromised patients

  • More trends:

    Pharmerica CorporationPMC | PHH CorpPHH | Philip Morris International IncPM | Philippine Long Distance Telephone CompanyPHI | Phillips 66PSX | Phillips 66 Partners LPPSXP | Phoenix CompaniesPFX | Phoenix CompaniesPNX | Phoenix New Media LimitedFENG | Physicians Realty TrustDOC |